<DOC>
	<DOC>NCT01447225</DOC>
	<brief_summary>To evaluate the safety and tolerability of escalating doses of MM-121 + certain anticancer therapies</brief_summary>
	<brief_title>Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This study was a Phase 1 and pharmacologic dose-escalation trial of MM-121 in combination with certain anticancer therapies. The dose-escalation portion of the study employed a 3 + 3 design to assess the safety, tolerability, and pharmacokinetics of MM-121 administered weekly in combination with certain anticancer therapies in patients with advanced/recurrent cancer. Doses of MM-121 and/or the anticancer therapy were escalated until either the MTD is identified or the combination was shown to be tolerable at the highest planned doses.</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Advancedstage solid tumors â‰¥ 18 years of age Adequate liver and kidney function Any other active malignancy No known HIV, Hepatitis C or B</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Advanced-stage</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>MM-121</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Cabazitaxel</keyword>
	<keyword>ErbB3</keyword>
	<keyword>Phase I</keyword>
	<keyword>Cancer</keyword>
</DOC>